Adiponectin and resistin modulate the progression of Alzheimer's disease in a metabolic syndrome model

Simple item page
dc.contributor.authorCisternas, Pedro
dc.contributor.authorGherardelli, Camila
dc.contributor.authorGutierrez, Joel
dc.contributor.authorSalazar, Paulina
dc.contributor.authorMendez-Orellana, Carolina
dc.contributor.authorWong, G. William
dc.contributor.authorInestrosa, Nibaldo C.
dc.date.accessioned2025-01-20T17:34:17Z
dc.date.available2025-01-20T17:34:17Z
dc.date.issued2023
dc.description.abstractMetabolic syndrome (MetS), a cluster of metabolic conditions that include obesity, hyperlipidemia, and insulin resistance, increases the risk of several aging-related brain diseases, including Alzheimer's disease (AD). However, the underlying mechanism explaining the link between MetS and brain function is poorly understood. Among the possible mediators are several adipose-derived secreted molecules called adipokines, including adiponectin (ApN) and resistin, which have been shown to regulate brain function by modulating several metabolic processes. To investigate the impact of adipokines on MetS, we employed a diet-induced model to induce the various complications associated with MetS. For this purpose, we administered a high-fat diet (HFD) to both WT and APP/PSN1 mice at a pre-symptomatic disease stage. Our data showed that MetS causes a fast decline in cognitive performance and stimulates A beta(42) production in the brain. Interestingly, ApN treatment restored glucose metabolism and improved cognitive functions by 50% while decreasing the A beta(42/40) ratio by approximately 65%. In contrast, resistin exacerbated Ab pathology, increased oxidative stress, and strongly reduced glucose metabolism. Together, our data demonstrate that ApN and resistin alterations could further contribute to AD pathology.
dc.fuente.origenWOS
dc.identifier.doi10.3389/fendo.2023.1237796
dc.identifier.issn1664-2392
dc.identifier.urihttps://doi.org/10.3389/fendo.2023.1237796
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/91655
dc.identifier.wosidWOS:001068605300001
dc.language.isoen
dc.revistaFrontiers in endocrinology
dc.rightsacceso restringido
dc.subjectadiponectin
dc.subjectresistin
dc.subjectobesity
dc.subjectAlzheimer ' s disease
dc.subjectglucose metabolism
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAdiponectin and resistin modulate the progression of Alzheimer's disease in a metabolic syndrome model
dc.typeartículo
dc.volumen14
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas